Kelly Boothe
Investor Relations Contact at Carmot Therapeutics, Inc.
Kelly Boothe active positions
| Companies | Position | Start | End |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - |
Career history of Kelly Boothe
Former positions of Kelly Boothe
| Companies | Position | Start | End |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - |
Statistics
International
| United States | 3 |
Operational
| Investor Relations Contact | 2 |
| Public Communications Contact | 2 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Kelly Boothe
- Experience
